The COVID Vaccine Challenges That Lie Ahead

This article originally appeared in Nature. Read the full article here

Large clinical trials of four vaccine candidates are showing remarkable promise, with three exceeding 90% efficacy — an unexpectedly high rate — according to results released so far. None reported worrying safety signals and one has shown promise in older adults, a demographic that is particularly vulnerable to SARS-CoV-2 but which sometimes responds less well to vaccines.

Early studies had shown that these candidate vaccines could stimulate an immune response. The latest trials show that this immune response can protect people against COVID-19 — a major achievement. Vaccine development is fraught with possibilities for failure, and even the most ardent optimist might not have expected to have a highly effective vaccine against a new virus less than a year after its genome was sequenced.

But there is still a vast amount of work for researchers and clinicians to do. First, they need to determine how well the vaccines work in people who are at high risk of COVID-19, including older individuals, people with obesity and those with diabetes. Second, it isn’t clear how well some of the vaccines protect against severe COVID-19. Third, it is also not clear to what extent the vaccines prevent those who have been vaccinated from passing the virus on to others.

At the same time, researchers and policymakers must consider how to deal with challenges not related to the vaccine candidates themselves. These include vaccine hesitancy; weariness with current public-health restrictions; and the staggering logistics of vaccinating the world population. Although the finishing line seems to be in sight, there is still much difficult terrain to cross.

Read more.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Delivering 270M+ COVID-19 vaccines at just $0.29 per dose: The Bangladesh experience

Bangladesh launched its COVID-19 vaccination program in February 2021 with the ambitious aim of reaching 80% of the population with two doses. The program used a phased approach, initially targeting priority groups, and expanding eligibility over time as supply ramped up. By June 2022, the country had achieved its goal—having delivered over 270 million COVID-19 … Read More

New evidence on the costing the delivery of COVID-19 vaccines in Mozambique and the Philippines

ThinkWell has released two new reports on the cost of delivering COVID-19 vaccines in Mozambique and the Philippines, aiming to support governments and address the knowledge gap on the cost of these vaccination programs. In partnership with the Universidade Eduardo Mondlane and Ateneo de Manila University, ThinkWell conducted retrospective, bottom-up costing studies, as well as … Read More

📣 Lessons from Moldova on the Use of Pharmacists to Increase Demand for COVID-19 Vaccinations

When the COVID-19 vaccines first launched in Moldova, vaccine confidence across the country was low, particularly among target populations. To combat this, Moldova launched a national campaign using pharmacists to increase awareness, confidence, and coverage of the vaccines. Linked recently sat down with Oxana Constantinova, Doctor Epidemiologist, Center for Public Health, Moldova, to understand the … Read More